To include your compound in the COVID-19 Resource Center, submit it here.

CG7870: Phase I/II

CEGE reported results of a U.S. Phase I/II dose escalation study of CG7870 in 23

Read the full 151 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE